Finalists Announced for 2018 Diabetes Innovation Challenge
Winners of $250,000 in Cash and In-Kind Prizes to be Announced at Live Event in Boston May 21, 2018. 

BOSTON, April 24, 2018 (GLOBE NEWSWIRE) — T1D Exchange, a nonprofit patient-centered research organization dedicated to accelerating novel treatments to improve the lives of people with type 1 diabetes (T1D), today announced that 10 academic research teams and early stage companies have been named as finalists in the 2018 Diabetes Innovation Challenge, a world-wide competition to identify, nurture and advance innovative scientific and clinical solutions for diabetes.

The announcement comes after proposals from 30 semi-finalists were reviewed by a panel of experts. Additionally, nearly 500 votes have been cast to date for a separate People’s Choice Award. In all, 60 proposals were received from 17 countries.

The opportunity for the community to review and vote for the People’s Choice Award recipient is unique to the Diabetes Innovation Challenge, and a centerpiece of the T1D Exchange mission to connect patients to researchers and innovators. Those who wish to review descriptions of the entries and cast their vote for their favorite proposal are encouraged to go to the Vote Now link. Voting ends May 19, 2018.

The 2018 Diabetes Innovation Challenge is presented by T1D Exchange with the generous support of lead sponsors, The Leona M. and Harry B. Helmsley Charitable Trust and JDRF. Major sponsors include the American Diabetes Association, Eli Lilly and Company and Lexicon Pharmaceuticals, Inc.

By the way, my FAVORITE is Capillary Biomedical, Inc., developed right here in Orange County, CA: A soft, multi-port, kink-proof cannula and comfortable, reliable infusion!!! 

You can directly view our “Kink-Proof Infusion” entry using this link:


Read more and REGISTER TO VOTEWhich innovation stands to improve the lives of those affected by diabetes? You decide.
Share This
Skip to content